共 50 条
Heart Failure in Patients with Chronic Kidney Disease
被引:7
|作者:
Xanthopoulos, Andrew
[1
]
Papamichail, Adamantia
[2
]
Briasoulis, Alexandros
[2
]
Loritis, Konstantinos
[2
]
Bourazana, Angeliki
[1
]
Magouliotis, Dimitrios E.
[3
]
Sarafidis, Pantelis
[4
]
Stefanidis, Ioannis
[5
]
Skoularigis, John
[1
]
Triposkiadis, Filippos
[6
]
机构:
[1] Univ Hosp Larissa, Dept Cardiol, Larisa 41110, Greece
[2] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Fac Med, Amyloidosis Ctr,Dept Clin Therapeut, Athens 15772, Greece
[3] Univ Thessaly, Dept Cardiothorac Surg, Unit Qual Improvement, Larisa 41110, Greece
[4] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol, Thessaloniki 54124, Greece
[5] Univ Thessaly, Fac Med, Dept Nephrol, Larisa 41110, Greece
[6] European Univ Cyprus, Sch Med, CY-2404 Nicosia, Cyprus
关键词:
chronic kidney disease;
heart failure;
beta-blockers;
renin-angiotensin aldosterone system inhibitors;
angiotensin receptor/neprilysin inhibitor;
sodium glucose cotransporter 2 inhibitor;
ANGIOTENSIN-CONVERTING ENZYME;
WORSENING RENAL-FUNCTION;
REDUCED EJECTION FRACTION;
BETA-BLOCKERS;
IRON-DEFICIENCY;
ALDOSTERONE BREAKTHROUGH;
ATHEROSCLEROSIS RISK;
DIALYSIS PATIENTS;
BLOOD-PRESSURE;
OUTCOMES;
D O I:
10.3390/jcm12186105
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The function of the kidney is tightly linked to the function of the heart. Dysfunction/disease of the kidney may initiate, accentuate, or precipitate of the cardiac dysfunction/disease and vice versa, contributing to a negative spiral. Further, the reciprocal association between the heart and the kidney may occur on top of other entities, usually diabetes, hypertension, and atherosclerosis, simultaneously affecting the two organs. Chronic kidney disease (CKD) can influence cardiac function through altered hemodynamics and salt and water retention, leading to venous congestion and therefore, not surprisingly, to heart failure (HF). Management of HF in CKD is challenging due to several factors, including complex interplays between these two conditions, the effect of kidney dysfunction on the metabolism of HF medications, the effect of HF medications on kidney function, and the high risk for anemia and hyperkalemia. As a result, in most HF trials, patients with severe renal impairment (i.e., eGFR 30 mL/min/1.73 m(2) or less) are excluded. The present review discusses the epidemiology, pathophysiology, and current medical management in patients with HF developing in the context of CKD.
引用
收藏
页数:18
相关论文